Saturday, February 25, 2017 10:26:35 AM
Personally, the way they talked at the last conference if Regabatin would be part of the deal they would have said something more like, "we are in or actively seeking to partner to further the drug" not make a statement its shelved until it is partnered. but it would make sense that Novartis would be interested in it to protect against Lyrica. Lyrica is going to go generic so whats better but to come out with a better upgrade of the drug to combat the generic threat?
regarding the details of the rumor, I do agree. while an additional 10 million shares would be dilutive, it then takes the total upfront to 85 to 90 million level depending on the 20 MDA. thats an automatic $2 to $3 per share value! and then lets not forget thats just the beginning, there are going to be additional milestones so the entire deal may be worth upwards of 400 million along with split in royalties.
plus the additional benefit is we would then have a huge shareholder whose input would be valued at directors meetings and that could then stop stupid management decisions such as bonuses for drug approvals which then don't get or cant get commercialized.
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - IPCI • PR Newswire (Canada) • 06/08/2023 05:30:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - IPCI • PR Newswire (Canada) • 06/08/2023 05:28:00 PM
- Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results • PR Newswire (Canada) • 06/06/2023 10:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM